Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis : A Real-Life Study
© 2023 S. Karger AG, Basel..
INTRODUCTION: Asthma is one of the most common chronic diseases and affects around 334 million people worldwide. The estimated prevalence of severe asthma is 3-10% of the asthmatic population. Mepolizumab has demonstrated efficacy in reducing exacerbations, oral corticosteroid use, and improving quality of life, asthma control, and lung function in patients with severe eosinophilic asthma (SEA). Our study aimed to check the response to mepolizumab in a series of severe asthma patients regarding exacerbations, oral corticosteroid use, asthma control, quality of life, and lung function and to compare the response between patients with and without nasal polyps.
METHOD: This is a retrospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) performed in eight hospitals of the Region of Murcia (Spain) under routine clinical practice conditions. We included patients diagnosed with SEA who completed at least 1 year of treatment with mepolizumab. We analyzed clinical characteristics, drug tolerance, and effectiveness: exacerbations, ACT, miniAQLQ, forced expiratory volume in 1 s (FEV1), and use of oral corticosteroids. We also compared the results between patients with and without nasal polyps.
RESULTS: The median of exacerbations before treatment was 3 and decreased to 0 after treatment (mean decrease of 77.4%). The median diary oral prednisone intake was 15 mg before treatment and 5 mg after treatment (mean 56% reduction). We have obtained a significant improvement in other variables: ED visits and hospitalizations, asthma control (ACT), quality of life (miniAQLQ), and lung function (FEV1). Thirty-four out of 70 patients (48.57%) fulfilled the criteria of super-responder, and 17 out of 70 (24.29%) had a complete response. More patients in the group with nasal polyps fulfilled the criteria of super-responder and complete response to mepolizumab.
CONCLUSIONS: Mepolizumab is a safe and effective treatment for SEA patients, improving exacerbations, oral corticosteroid intake, asthma control, quality of life, and lung function. In patients with associated nasal polyposis, there is a statistically significant higher proportion of super-responders and complete responders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:185 |
|---|---|
| Enthalten in: |
International archives of allergy and immunology - 185(2024), 3 vom: 30., Seite 253-259 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bravo-Gutiérrez, Francisco Javier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
90Z2UF0E52 |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000534902 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365266841 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365266841 | ||
| 003 | DE-627 | ||
| 005 | 20240305232055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000534902 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM365266841 | ||
| 035 | |a (NLM)38035559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bravo-Gutiérrez, Francisco Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis |b A Real-Life Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: Asthma is one of the most common chronic diseases and affects around 334 million people worldwide. The estimated prevalence of severe asthma is 3-10% of the asthmatic population. Mepolizumab has demonstrated efficacy in reducing exacerbations, oral corticosteroid use, and improving quality of life, asthma control, and lung function in patients with severe eosinophilic asthma (SEA). Our study aimed to check the response to mepolizumab in a series of severe asthma patients regarding exacerbations, oral corticosteroid use, asthma control, quality of life, and lung function and to compare the response between patients with and without nasal polyps | ||
| 520 | |a METHOD: This is a retrospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) performed in eight hospitals of the Region of Murcia (Spain) under routine clinical practice conditions. We included patients diagnosed with SEA who completed at least 1 year of treatment with mepolizumab. We analyzed clinical characteristics, drug tolerance, and effectiveness: exacerbations, ACT, miniAQLQ, forced expiratory volume in 1 s (FEV1), and use of oral corticosteroids. We also compared the results between patients with and without nasal polyps | ||
| 520 | |a RESULTS: The median of exacerbations before treatment was 3 and decreased to 0 after treatment (mean decrease of 77.4%). The median diary oral prednisone intake was 15 mg before treatment and 5 mg after treatment (mean 56% reduction). We have obtained a significant improvement in other variables: ED visits and hospitalizations, asthma control (ACT), quality of life (miniAQLQ), and lung function (FEV1). Thirty-four out of 70 patients (48.57%) fulfilled the criteria of super-responder, and 17 out of 70 (24.29%) had a complete response. More patients in the group with nasal polyps fulfilled the criteria of super-responder and complete response to mepolizumab | ||
| 520 | |a CONCLUSIONS: Mepolizumab is a safe and effective treatment for SEA patients, improving exacerbations, oral corticosteroid intake, asthma control, quality of life, and lung function. In patients with associated nasal polyposis, there is a statistically significant higher proportion of super-responders and complete responders | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a News | |
| 650 | 4 | |a Effectiveness | |
| 650 | 4 | |a Mepolizumab | |
| 650 | 4 | |a Nasal polyps | |
| 650 | 4 | |a Severe eosinophilic asthma | |
| 650 | 4 | |a Super-responders | |
| 650 | 7 | |a mepolizumab |2 NLM | |
| 650 | 7 | |a 90Z2UF0E52 |2 NLM | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Miralles-López, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Valverde-Molina, José |e verfasserin |4 aut | |
| 700 | 1 | |a Alemany Francés, María Loreto |e verfasserin |4 aut | |
| 700 | 1 | |a Andújar-Espinosa, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Castilla-Martínez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Avilés-Inglés, María Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Mora-González, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Pajarón-Fernández, Manuel José |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrejos-Perotti, Sheila |e verfasserin |4 aut | |
| 700 | 1 | |a Meseguer-Arce, José |e verfasserin |4 aut | |
| 700 | 1 | |a Flores Martín, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Fernández, Virginia |e verfasserin |4 aut | |
| 700 | 0 | |a RE-ASGRAMUR Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International archives of allergy and immunology |d 1992 |g 185(2024), 3 vom: 30., Seite 253-259 |w (DE-627)NLM012632554 |x 1423-0097 |7 nnns |
| 773 | 1 | 8 | |g volume:185 |g year:2024 |g number:3 |g day:30 |g pages:253-259 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000534902 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 185 |j 2024 |e 3 |b 30 |h 253-259 | ||